SYRS Oct 2024 2.500 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 03:26PM EDT. Market open.
| Previous Close | 3.2100 |
| Open | 3.2100 |
| Bid | 2.8000 |
| Ask | 6.0000 |
| Strike | 2.50 |
| Expire Date | 2024-10-18 |
| Day's Range | 3.2100 - 3.2100 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 501 |
Business WireSyros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
CAMBRIDGE, Mass., June 13, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a webcast event with medical experts to discuss the unmet need in higher-risk myelodysplastic syndrome (HR-MDS) and the opportunity for tamibarotene to transform the care of newly diagnosed patients with RARA gene overexpression. The event will take place on Tuesday
- GuruFocus.com
Syros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Explore key updates on clinical trials, financial shifts, and strategic insights from Syros Pharmaceuticals' Q1 2024 earnings call.
- Thomson Reuters StreetEvents
Q1 2024 Syros Pharmaceuticals Inc Earnings Call
Q1 2024 Syros Pharmaceuticals Inc Earnings Call
© 2024 Yahoo. All rights reserved.